Prognostic Interest of Vasorin in Septic Shock

Status

Completed

Phases

Unknown

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06072508

Acronym

VASO-SHOCK

Enrollment

Registered

2023-10-10

Start date

2023-07-03

Completion date

2025-03-29

Last updated

2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Kidney Injury, Sepsis

Keywords

vasorin, Sepsis, angiotensin II, Acute Kidney Injury

Brief summary

In septic shock, the intensity and duration of low blood pressure can lead to a critical reduction in renal tissue perfusion and lead to the onset of more or less severe Acute Kidney Injury (AKI). Vasorin (Vasn) is a protein strongly expressed in large vessels and kidneys, whose functions are still poorly known. Previous experimental studies show that Vasn is associated with decreased Angiotensin II concentrations, a vessel contractility defect and early mortality. The investigators hypothesize that Vasn (the potential direct regulator of blood pressure) would be an early biomarker predicting the severity of AKI post septic shock, which may be associated with mortality from septic shock or lead to longer-term Chronic Renal Failure (CKD).

Interventions

BIOLOGICALBlood sampling

Blood sampling (at day 0 and day 3) for Vasn, Angiotensin 2 and clotting markers.

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

OTHER

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Age ≥18 years old. * Hospitalized in intensive care or medical resuscitation units. * With a septic shock state defined by 2 mmol/l lactate sepsis, requiring vasopressors to maintain mean blood pressure 65 mmHg (despite adequate vascular filling). * Whether or not they have developed AKI. * Patient/family information and collection of non opposition

Exclusion criteria

* Patients with chronic respiratory failure. * Pregnant women. * Patients in palliative care. * Information for the patient/someone close and collection of his opposition

Design outcomes

Primary

Measure	Time frame
correlation between vasorin concentration at day 0 and mortality rate	day 0
correlation between vasorin concentration at day 3 and mortality rate	day 3

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026